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Endotoxemia Through an IL-10
STAT3-Dependent Mechanism
Protein tyrosine phosphatase-1B (PTP1B) negatively
regulates insulin and leptin signaling, rendering it an
attractive drug target for treatment of obesity-induced
insulin resistance. However, some studies suggest
caution when targeting macrophage PTP1B, due to its
potential anti-inﬂammatory role. We assessed the role
of macrophage PTP1B in inﬂammation and whole-
body metabolism using myeloid-cell (LysM) PTP1B
knockout mice (LysM PTP1B). LysM PTP1Bmice were
protected against lipopolysaccharide (LPS)-induced
endotoxemia and hepatic damage associated with
decreased proinﬂammatory cytokine secretion in vivo.
In vitro, LPS-treated LysM PTP1B bone marrow–
derived macrophages (BMDMs) displayed increased
interleukin (IL)-10 mRNA expression, with
a concomitant decrease in TNF-amRNA levels. These
anti-inﬂammatory effects were associated with
increased LPS- and IL-10–induced STAT3
phosphorylation in LysM PTP1B BMDMs. Chronic
inﬂammation induced by high-fat (HF) feeding led to
equally beneﬁcial effects of macrophage PTP1B
deﬁciency; LysM PTP1B mice exhibited improved
glucose and insulin tolerance, protection against LPS-
induced hyperinsulinemia, decreased macrophage
inﬁltration into adipose tissue, and decreased liver
damage. HF-fed LysM PTP1B mice had increased
basal and LPS-induced IL-10 levels, associated with
elevated STAT3 phosphorylation in splenic cells, IL-10
mRNA expression, and expansion of cells expressing
myeloid markers. These increased IL-10 levels
negatively correlatedwith circulating insulin and alanine
transferase levels. Our studies implicatemyeloid PTP1B
in negative regulation of STAT3/IL-10–mediated
signaling, highlighting its inhibition as a potential anti-
inﬂammatory and antidiabetic target in obesity.
Diabetes 2014;63:456–470 | DOI: 10.2337/db13-0885
Protein tyrosine phosphatase-1B (PTP1B) is a non-
receptor tyrosine phosphatase, identiﬁed as an attractive
drug target for conditions associated with metabolic
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syndrome as well as potential anticancer therapeutic due to
its diverse involvement in regulation of various cell signal-
ing cascades. Evidence to support the notion that PTP1B
inhibition may be beneﬁcial in states of overnutrition and
insulin resistance was demonstrated in mice with a global-
(1,2) as well as tissue-speciﬁc PTP1B deletion (3–6).
Insulin resistance in adipose, muscle, and liver is ex-
acerbated in obese states, due to the underlying presence
of chronic low-grade inﬂammation and macrophage in-
ﬁltration into these tissues. White adipose tissue (WAT)
from obese subjects contains greater numbers of in-
ﬁltrating proinﬂammatory macrophages in comparison
with lean counterparts, and these cells secrete cytokines
such as tumor necrosis factor-a (TNF-a), interleukin
(IL)-1b, and IL-6, which can impair systemic insulin
sensitivity (7–11). This process is enhanced further by
the release of chemokines, such as monocyte chemo-
attractant protein-1, which recruits more
activated tissue-macrophages into WAT (12). Satu-
rated fatty acids are able to directly induce the ex-
pression of these proinﬂammatory cytokines via
activation of the nuclear factor (NF)-kB pathway, and
the receptor primarily responsible for potentiating this
effect has been identiﬁed as the macrophage toll-like
receptor (TLR)-4 (13). Mice with myeloid-TLR-4 de-
letion are protected against high-fat diet (HFD)-
induced inﬂammation, adipose macrophage inﬁltration,
and insulin resistance (14).
It has been postulated that PTP1B may act as a nega-
tive regulator of TLR-4 signaling in macrophages since in
vitro PTP1B knockdown in the RAW 264.7 macrophage
cell line resulted in elevated production of TNF-a, IL-6,
and interferon (IFN)-b following challenge with a variety
of TLR ligands (15). PTP1B overexpression in the same
cell line caused a concomitant decrease in proin-
ﬂammatory cytokine production in response to lipo-
polysaccharide (LPS) and palmitate challenge (15,16).
Similarly, splenic macrophages isolated from global
PTP1B2/2 mice were found to be highly sensitive to LPS-
induced inducible nitric oxide synthase (iNOS) expres-
sion and nitric oxide production, in addition to elevated
IFN-g–induced phosphorylation of STAT1 (17). In the
same study, in vivo LPS-challenge increased sensitivity to
endotoxic-shock in PTP1B2/2 mice, associated with in-
creased systemic production of IL-12 and IFN-g. How-
ever, since these studies were performed in mice with
global PTP1B deletion, and PTP1B regulation of cell
function/signaling varies in a cell-speciﬁc manner (3–6),
we set out to deﬁnitively establish the in vivo role of
macrophage PTP1B by assessing the regulation of in-
ﬂammation and whole-body metabolism in LysM PTP1B
knockout mice.
RESEARCH DESIGN AND METHODS
Animal Studies
All animal procedures were performed under a project
license approved by the U.K. Home Ofﬁce under the
Animals (Scientiﬁc Procedures) Act 1986 (PPL60/3951).
PTP1Bﬂ/ﬂ and mice expressing Cre recombinase (Cre)
under the control of the LysM promoter have been de-
scribed previously (3). To generate myeloid PTP1B2/2
mice, PTP1Bﬂ/ﬂ mice were crossed with LysM Cre mice
(18) and back crossed nine times to pure C57BL/6J mice.
DNA extraction and genotyping were performed as de-
scribed previously (3). Age-matched male mice were
studied and compared with PTP1Bﬂ/ﬂ and LysM Cre
control littermates. Mice were group housed and main-
tained at 22–24°C on 12-h light/dark cycle with free
access to food/water. At weaning (21 days), mice were
placed on standard 3.4% fat chow-pellet diet (Rat and
Mouse Breeder and Grower, Special Diets Services, DBM
Food Hygiene Supplies, Broxburn, U.K.) or HFD (Adjusted
Calories Diet, 55% fat, Harlan Teklad) for 29 weeks and
weight recorded weekly. The approximate fatty-acid pro-
ﬁle of Adjusted Calories Diet (percentage total fat) was
28% saturated, 30% trans, 28% monounsaturated (cis),
and 14% polyunsaturated (cis). For endotoxemia experi-
ments, 50-week-old chow-fed and high-fat (HF)-fed mice
were fasted for 2 h and injected intraperitoneally with LPS
(1 and 0.5 mg/kg, respectively; Merck). Mice were ob-
served for signs of sepsis, including reduced mobility, fur
rufﬂing, and conjunctivitis (19). At 24 or 3 h post-LPS
injection (stated in ﬁgure legends), mice were killed by
cervical dislocation and tissues/blood were harvested (3).
Blood Analysis
Tail-blood glucose from fasted (5 h) mice was measured
using glucometers (Accu-Chek, Burgess Hill, U.K.) (6).
Serum TNF-a, IL-6, monocyte chemoattractant protein-1,
insulin, leptin, plasminogen activator inhibitor-1, and
resistin were measured using adipokine multiplex kit
(Millipore, U.K.), and serum IL-10 levels were determined
by ELISA (R&D Systems, Minneapolis, MN). Alanine
aminotransferase (ALT; BioVision) and serum glucose
(Thermo Scientiﬁc) levels were assayed per the manu-
facturer’s instructions. Glucose tolerance tests (GTTs) and
insulin tolerance tests (ITTs) were performed as previously
described (2,6). For hematocrit-level determination, whole
blood was collected in heparinized microhematocrit cap-
illary tubes and centrifuged for 3 min. The percentage
hematocrit value was determined by measuring the length
of the red blood cell layer and calculating as a percentage
of the total height of the column sample.
Isolation of T-cells
Single-cell suspensions were made from spleens and
lymph nodes by pressing through a 70 mm strainer (BD
Falcon). After red blood cell lysis (Sigma), cells were la-
beled with anti-L3T4 (CD4) microbeads (Milteny Biotec)
and sorted using LS-Columns (Milteny Biotec).
Isolation and Stimulation of Bone Marrow–Derived
Macrophages
Bone marrow–derived macrophages (BMDMs) were
obtained by ﬂushing out femurs and tibiae with sterile
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Figure 1—LysM PTP1B mice have unaltered glucose homeostasis but display an anti-inﬂammatory phenotype following in vivo challenge
with low-dose LPS when compared with control littermates. A: Immunoblot depicting macrophage-speciﬁc deletion of PTP1B in LysM
PTP1B mice fed chow diet compared with littermate controls. Tissues shown are (left to right) BMDM, WAT, liver, and muscle. Blot was
reprobed for SHP2, SHP1, and T-cell protein tyrosine phosphatase in addition to b-actin as a loading control to conﬁrm speciﬁcity of
PTP1B deletion. B: PTP1B levels were maintained in CD4+ T-cells harvested from LysM PTP1B mice and were not different from control
cells. C: Immunoblot displaying PTP1B, SHP2, and b-actin protein levels in BMDM isolated from control mice (n = 5) compared with LysM
PTP1B (n = 4). D: Corresponding quantiﬁcation data of PTP1B protein levels relative to b-actin, demonstrating a PTP1B deletion efﬁciency
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PBS (Lonza), as described previously (6). Mature mac-
rophages were seeded in six-well tissue-culture plates
(1 3 106 cells/well) and serum starved for 16 h prior to
stimulation with 100 ng/ml LPS (InvivoGen), 10 ng/ml
IL-10 (Peprotech), or 20 ng/ml IL-6 (Peprotech).
PTP1B Stable Knockdown Macrophages
Stable knockdown of PTP1B in RAW 264.7 cells (murine-
macrophage cell line) was performed using short-hairpin
RNA constructs as previously described (20).
Immunoblotting
Cells and tissues were lysed in radioimmunoprecipitation
assay buffer containing fresh sodium orthovanadate and
protease inhibitors (21). Proteins were separated by
4–12% SDS-PAGE and transferred to nitrocellulose
membranes. Immunoblots were performed using antibodies
from cell signaling (New England Biolabs, Hitchin, U.K.;
unless stated otherwise) against phosphorylated extracel-
lular signal–related kinase (ERK)1/2, mitogen-activated
protein kinase (MAPK) T202/Y204, phosphorylated IkB
kinase (IKK) a/b S176/S180, IkBa, p-c-jun S63, phos-
phorylated P38 T180/Y182, phosphorylated STAT1 Y701,
phosphorylated STAT3 Y705, STAT3, BCL-2, iNOS, SHP1,
phosphorylated Akt/PKBS473, phosphorylated S6 ribo-
somal protein S235/236, phosphorylated GSK 3a/b,
phosphorylated IR Y1162/1163 (Invitrogen), SHP2 (Santa
Cruz), ERK2 (Santa Cruz), T-cell protein tyrosine phos-
phatase (R&D Systems), phosphorylated JNK/SAPK
T183/Y185 (R&D Systems), b-actin (Sigma), and PTP1B
(Millipore). Immunoblots were visualized using enhanced
chemiluminescence and quantiﬁed by densitometry scan-
ning using Bio1D-software (PeqLab, Fareham, U.K.).
Gene Expression Analysis
Cells/tissues were homogenized in TriFast reagent
(Peqlab, Sarisbury Green, U.K.) (20). cDNA synthesis was
carried out from 1 mg of RNA using Tetro cDNA-
synthesis kit (Bioline). Quantitative real-time PCR was
performed using Light-Cycler 480 (Roche), and gene ex-
pression of iNOS, TNF-a, IL-6, MCP1, IL-1b, IL-1a, IL-10,
and BCL2 was determined relative to the most stable
of 77% in LysM PTP1B BMDM compared with control levels. E: Mean body weight of male mice that had been back crossed to C57BL/6J
background for nine generations was unchanged when LysM PTP1B (n = 6) were compared with control littermates fed standard 3.4% fat
chow pellet diet for 10 weeks after weaning (n = 6). F and G: GTTs revealed no differences in the ability of LysM PTP1B to clear glucose
when compared with control mice (F), and ITTs demonstrated no differences between genotypes (G). Forty-eight-week-old control mice
(n = 5) and LysM PTP1B littermates (n = 4) were injected with 1 mg/kg LPS intraperitoneally. Photographs showing an example of a control
mouse (H) compared with a LysM PTP1B mouse (I ) 24 h after receiving 1 mg/kg LPS. Control mice exhibited more severe signs of en-
dotoxic shock compared with mutant mice, which were in better health. J: Phosphorylation levels of STAT1 (Y701) and STAT3 (Y705) in liver
tissue harvested following LPS injection were lower in LysM PTP1B mice compared with controls. K: Control, white bars; LysM PTP1B,
black bars. Data are expressed as mean 6 SEM. TC-PTP, T-cell protein tyrosine phosphatase; pSTAT, phosphorylated STAT. **P < 0.01,
***P < 0.001.
Table 1—Fed and fasted metabolic parameters (chow)
Analyte Genotype Fed levels Signiﬁcance level Fasted levels Signiﬁcance level
Chow diet
Glucose (mg/dL) Control 165.21 6 10.79 P = 0.14 112.87 6 10.16 P = 0.69
LysM PTP1B 143.49 6 4.87 106.89 6 9.87
Insulin (ng/mL) Control 3.09 6 0.20 P = 0.93 0.67 6 0.12 P = 0.59
LysM PTP1B 3.16 6 0.90 0.76 6 0.11
Leptin (ng/mL) Control 13.25 6 1.41 P = 0.09 5.44 6 0.99 P = 0.11
LysM PTP1B 17.33 6 1.43 8.40 6 1.29
Free fatty acids (mmol/L) Control 1.51 6 0.11 P = 0.28 2.55 6 0.13 P = 0.37
LysM PTP1B 1.35 6 0.07 2.78 6 0.23
HFD
Glucose (mg/dL) Control 172.6 6 5.39 P = 0.86 177.0 6 12.37 P = 0.33
LysM PTP1B 174.5 6 9.83 197.0 6 5.60
Insulin (ng/mL) Control 3.92 6 0.38 P = 0.25 1.32 6 0.22 P = 0.71
LysM PTP1B 3.14 6 0.44 1.17 6 0.25
Leptin (ng/mL) Control 23.84 6 1.85 P = 0.69 14.38 6 1.67 P = 0.56
LysM PTP1B 25.28 6 3.37 16.60 6 4.27
Free fatty acids (mmol/L) Control 1.54 6 0.05 P = 0.86 1.65 6 0.04 P = 0.46
LysM PTP1B 1.52 6 0.13 2.02 6 0.80
Data from chow-fed control (n = 5) or LysM PTP1B (n = 4) mice and HFD-fed control (n = 12) and LysM PTP1B (n = 6) mice are
represented as mean 6 SEM. Data were analyzed using two-tailed Student’s t test (P , 0.05).
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reference gene (YWhaz, NoNo, or b-actin), which was
identiﬁed using a Web-based reference gene assessment
tool (http://www.leonxie.com/referencegene.php?
type=reference). Primer sequences are provided in the
Supplementary Data online.
Cytokine Quantiﬁcation
TNF‐a, IL-6, and IL-10 concentrations in BMDM super-
natants were quantiﬁed by ELISA (R&D Systems) or
multiplex ELISA (Millipore), according to the manu-
facturers’ instructions.
Nitrite Determination
Nitric oxide production by BMDMs was quantiﬁed by
determining the concentration of nitrite present in
supernatants using Griess reaction (22).
Adipose Immunohistochemical Staining
Ethanol-ﬁxed, parafﬁn-embedded adipose tissue sections
were stained as previously described (23) using rat
antimouse F4/80 (AbD Serotec MCA497RT), CD68
(Abcam ab31630), and iNOS (Cell Signaling).
Hematoxylin and Eosin Staining
Liver and spleen tissue was ﬁxed in formaldehyde, em-
bedded in parafﬁn, sectioned, and stained with hema-
toxylin and eosin.
Flow Cytometry
Single-cell suspensions were made by pressing spleens
through cell strainers, and cell suspensions were centri-
fuged at 900g for 5 min. Red blood cells were lysed for
1 min with red blood cell lysis buffer (Sigma) and washed
by centrifugation at 900g for 5 min in PBS without Ca2+
and Mg2+, 5% fetal bovine serum, and 5 mmol/L EDTA.
We blocked 1 3 106 cells per label for 30 min in the dark
with rat anti-mouse CD16/CD32 (BD, 0.5 mg/reaction)
and then labeled them with optimized quantities of
antibodies (PerCP-Cy5.5 [BD 550954], CD8 V450
[BD 560469], CD3 AF488 [BD 557666], CD45 PE
[BD 553089], CD11b AF488 [BD 557672], CD11c V450
[BD 560521], Gr1 APC-Cy7 [BD 557661], MHC-II PE
[BD 557000], Ly6C PerCP-Cy5.5 [BD 560602], Ly6G APC
[BD 560595], F4/80-AF647 [AbD Serotech]). Data were
acquired on BD LSR II and analyzed using DiVa software.
Data Analysis
Data are expressed as mean 6 SEM. Statistical analyses
were performed using correlation analyses, one-way
ANOVA with Tukey’s multiple comparison post-tests,
two-way ANOVA with Bonferroni multiple comparisons
post-tests, and two-tailed Student’s t tests, as appropri-
ate, using GraphPad Prism 5 statistical software.
Table 2—Analysis of serum obtained from control and LysM PTP1B 3 and 24 h following 1 mg/kg LPS injection
Analyte (ng/mL) Genotype 3 h post-LPS Signiﬁcance level 24 h post-LPS Signiﬁcance level
CHOW
TNF-a Control 0.38 6 0.03 P = 0.38 0.10 6 0.03 P = 0.18
LysM PTP1B 0.47 6 0.07 0.04 6 0.005
IL-6 Control 149.0 6 10.31 P = 0.25 14.3 6 5.3 P = 0.09
LysM PTP1B 134.4 6 12.30 3.7 6 0.9
IL-10 Control 0.67 6 0.03 P = 0.12 0.73 6 0.13 P = 0.7
LysM PTP1B 0.89 6 0.12 0.65 6 0.07
MCP-1 Control ND 3.46 6 1.60 P = 0.3
LysM PTP1B ND 1.54 6 1.80
Insulin Control ND 3.30 6 0.96 P = 0.5
LysM PTP1B ND 2.50 6 0.36
Resistin Control ND 7.54 6 1.87 P = 0.5
LysM PTP1B ND 6.00 6 0.84
PAI-1 Control ND 7.41 6 0.65 P = 0.08
LysM PTP1B ND 11.71 6 1.90
Analyte (ng/mL) Genotype Basal Signiﬁcance level 3 h post-LPS Signiﬁcance level
HFD
TNF-a Control ND 1.44 6 0.28 P = 0.2
LysM PTP1B ND 2.10 6 0.30
IL-6 Control 0.03 6 0.004 P = 0.07 60.78 6 4.45 P = 0.5
LysM PTP1B 0.11 6 0.07 54.98 6 10.41
MCP-1 Control 0.06 6 0.006 P = 0.1 55.99 6 25.43 P = 0.5
LysM PTP1B 0.04 6 0.01 31.46 6 14.46
PAI-1 Control 5.00 6 1.14 P = 0.3 5.15 6 0.43 P = 0.09
LysM PTP1B 6.88 6 1.06 7.84 6 1.97
Data from 3 h (n = 6 per genotype) and 24 h (control mice, n = 5; LysM PTP1B, n = 4) LPS-injected mice. Multiplex analysis was used
for 24 h time points (TNF-a, IL-6, insulin, resistin, plasminogen activator inhibitor 1 [PAI-1]) and ELISA used for the remaining time
points/analytes. Data are represented as mean 6 SEM and analyzed using two-tailed Student’s t test (P , 0.05). ND, not determined
or too low to detect.
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Figure 2—BMDMs isolated from LysM PTP1B have increased IL-10 and iNOS and decreased TNF‐a gene expression and protein in
response to LPS. Treatment of BMDMs isolated from LysM PTP1B mice (n = 4) and control mice (n = 4) with 100 ng/ml LPS for 4 and 24 h
revealed an increase in IL-10 mRNA levels (P # 0.05; one-tailed t test) (A) and STAT3 mRNA levels (4 h post-LPS, P # 0.01; two-tailed
t test) (B) in the absence of PTP1B. C: Levels of proinﬂammatory TNF-a transcripts were downregulated in LysM PTP1B cells compared
with control cells following 4 h challenge with LPS (P # 0.05; two-tailed t test). D: iNOS mRNA expression was elevated in LysM PTP1B
BMDMs following 4 h LPS challenge (P# 0.05, respectively; two-tailed t test). Expression levels were calculated relative to the most stable
reference genes (b-actin, YWhaz, or NoNo). E and F: Supernatants harvested from LysM PTP1B macrophages following 6 h treatment with
100 ng/ml LPS contained higher levels of IL-10 (E) and lower levels of TNF-a (F) compared with control supernatants (P # 0.05; two-tailed
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RESULTS
LysM PTP1B Mice Are Protected Against LPS-Induced
Endotoxemia
PTP1B deletion was achieved in BMDMs isolated from
LysM PTP1B mice, without affecting PTP1B levels in
WAT, liver, muscle (Fig. 1A) or CD4+ T-cells (Fig. 1B).
A deletion efﬁciency of ;75% was determined in LysM
PTP1B BMDMs (n = 4) compared with controls (n = 5)
(Fig. 1C and D). There were no body weight differences
(Fig. 1E), and glucose (GTT) and insulin (ITT) tolerance
were unaltered between LysM PTP1B and control mice
on chow diet (Fig. 1F and G, respectively). Fed and fasted
metabolic parameters were unchanged in the absence of
myeloid PTP1B (Table 1). To establish whether macro-
phage PTP1B plays a role in TLR-4 signaling, LysM
PTP1B mice with conﬁrmed PTP1B deletion (Fig. 1C) and
littermate controls were injected with low-dose LPS
(1 mg/kg), and their response to endotoxin was
monitored. Twenty-four hours post-LPS, control mice
exhibited obvious signs of endotoxemia, including closed
eyes, shivering, reduced mobility, and rufﬂed fur (Fig. 1H
and Supplementary Videos 1 and 2), whereas LysM
PTP1B littermates were completely protected (Fig. 1I and
Supplementary Videos 3 and 4). LysM PTP1B mice had
decreased serum TNF-a and IL-6 levels compared with
controls, although this did not reach signiﬁcance (TNF-a,
0.04 6 0.005 vs. 0.1 6 0.03 ng/ml, respectively [P =
0.18; two-tailed t test]; IL-6, 3.7 6 0.9 vs. 14.3 6 5.3
ng/ml, respectively [P = 0.06; two-tailed t test]) (Table 2).
At 3 h post-LPS, there was also a trend toward increased
IL-10 levels in LysM PTP1B mice (0.89 6 0.12 vs.
0.67 6 0.03 ng/ml [P = 0.12; two-tailed t test]), although
this was not observed at 24 h post-LPS (Table 2). Fur-
thermore, levels of hepatic STAT1 and STAT3 phos-
phorylation were signiﬁcantly lower in LysM PTP1B
mice, indicative of decreased LPS-induced hepatic in-
ﬂammation (Fig. 1J and K).
LysM PTP1B Macrophages Exhibit Altered Cytokine
Kinetics
To assess whether the anti-inﬂammatory phenotype ob-
served in LPS-challenged LysM PTP1B mice is due spe-
ciﬁcally to the absence of macrophage PTP1B, isolated
BMDMs were stimulated with 100 ng/ml LPS for varying
durations up to 24 h in vitro.
Elevations in IL-10 mRNA expression in LysM PTP1B
BMDMs following LPS stimulation were observed at both
4 and 24 h (Fig. 2A), which was associated with increased
STAT3 mRNA expression 4 h post-LPS treatment (Fig. 2B).
TNF-a transcript levels were concomitantly downregulated
following 4 h of LPS treatment in LysM PTP1B cells (Fig.
2C). Supplementary Table 1 displays additional measures
of proinﬂammatory cytokines and markers of M1 and
M2 macrophages.
In keeping with previously published data showing
that isolated macrophages from global PTP1B2/2 mice
are highly sensitive to LPS-induced iNOS expression (17),
we also found increased levels of LPS-stimulated iNOS
mRNA transcript in the absence of macrophage PTP1B
(Fig. 2D). Supernatants harvested from LysM PTP1B
BMDMs challenged with LPS for 6 h contained increased
IL-10 (Fig. 2E) and decreased TNF-a levels (Fig. 2F).
Supernatant nitrite (Fig. 2G) and iNOS protein levels (Fig.
2H and I) were higher in LPS-stimulated LysM PTP1B
macrophages compared with respective control cells.
Macrophage PTP1B Regulates Janus Kinase/STAT
Signaling in LPS- and IL-10–Treated LysM PTP1B
Macrophages and RAW 264.7 Stable Knockdown Cells
We found increased levels of phosphorylated STAT1
a and b isoforms in LysM PTP1B macrophages treated
with LPS for 24 h (Fig. 3A and C), which is in agreement
with previous reports and is a likely explanation for the
elevated iNOS and nitrite levels produced by these cells
(17). The level of phosphorylated STAT3 was also sig-
niﬁcantly increased in LysM PTP1B cells following 24 h
of treatment with 100 ng/ml LPS (Fig. 3B and C). The
ability of endogenous IL-10 to directly induce STAT3
activation is a likely cause for the heightened levels of
phosphorylated STAT3 observed in PTP1B-deﬁcient
macrophages since the levels of IL-10 detected in re-
spective supernatants were also elevated (24).
To assess this, LysM PTP1B and control macrophages
were stimulated with IL-10 for varying durations, and
levels of STAT3 phosphorylation were determined (Fig.
3D). IL-6, which also activates STAT3, was used to allow
for a direct comparison (Fig. 3E). An elevation in IL-10–
induced phosphorylated STAT3 was observed following
60- and 120-min stimulation (Fig. 3F) in the absence of
macrophage PTP1B, which was not the case for IL-6–
induced STAT3 phosphorylation (data not shown). There
was a negative correlation between PTP1B protein levels
present in each cell batch (Fig. 3G) and the quantity
of phosphorylated STAT3, following 120-min IL-10 treat-
ment (Fig. 3H), suggesting a dose-dependent effect of
STAT3 dephosphorylation by PTP1B. RAW 264.7 cells with
PTP1B stable knockdown (Fig. 3I) also showed increased
LPS-induced phosphorylated STAT1-Y701 (Fig. 3J), phos-
phorylated STAT3-Y705, and iNOS (Fig. 3K) and increased
IL-10–induced phosphorylated STAT3-Y705 (Fig. 3L).
t test). G: Nitrite levels were increased in supernatants harvested from LysM PTP1B BMDMs stimulated for 24 h with 100 ng/ml LPS
compared with respective controls (P # 0.05; two-tailed t test). H and I: Quantiﬁcation (H) of immunoblot (I) showing elevated iNOS protein
levels in LysM PTP1B compared with control BMDM cells following challenge with 100 ng/ml LPS for 24 h (P # 0.05; two-tailed t test).
Control, white bars; LysM PTP1B, black bars. Data are expressed as mean 6 SEM. *P < 0.05, **P < 0.01.
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Figure 3—LysM PTP1B BMDMs and a RAW 264.7 macrophage cell line with PTP1B knockdown display increased LPS-induced
phosphorylation of STAT1 and STAT3 and increased IL-10–induced phosphorylated STAT3 in vitro when compared with control cells.
A and B: Immunoblot showing levels of phosphorylated STAT1 (Y701) (A) and phosphorylated STAT3 (Y705) (B) in control and LysM
PTP1B BMDMs stimulated with 100 ng/ml LPS for 24 h. C: Levels of phosphorylated STAT1 a (P# 0.01; two-tailed t test) and b (P# 0.01;
two-tailed t test) and phosphorylated STAT3 (P # 0.05; two-tailed t test) were elevated in LPS-treated LysM PTP1B BMDMs compared
with control cells (phosphorylated STAT proteins are expressed relative to relevant total STAT protein). Immunoblot showing levels of
phospho-STAT3 protein in LysM PTP1B and control BMDMs induced by 10 ng/ml IL-10 (D) and 20 ng/ml IL-6 (E) for 30, 60, and 120 min.
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Previous studies implicated macrophage PTP1B in
negative regulation of MAPK and NF-kB signaling cas-
cades, initiated by various TLR ligands (15). In our study,
macrophage PTP1B deﬁciency in vitro did not affect
phosphorylation of c-Jun (component of MAPK signal-
ing) (Supplementary Fig. 1) or phosphorylation of p65
(data not shown) and associated degradation of IkBa
(components of NF-kB signaling) (Supplementary Fig. 1),
following LPS stimulation at various time points. More
detailed analysis of these pathways revealed no alter-
ations in the levels of phosphorylated ERK1/2 (Supple-
mentary Fig. 2), p38, JNK1/2, or IKK (Supplementary
Fig. 3).
LysM PTP1B Mice Show Improved Glucose
Homeostasis in a Model of HFD Feeding, Protection
Against LPS-Induced Hyperinsulinemia, and
Decreased WAT Inﬂammation and Hepatic Damage
Since LysM PTP1B mice were protected from an acute
inﬂammatory challenge, we tested in vivo effects of
myeloid PTP1B deﬁciency under states of chronic low-
grade inﬂammation, caused by long-term (29 weeks)
HFD feeding (23).
Despite no alterations in body weight (Fig. 4A), GTTs
revealed improved ability to clear exogenous glucose in
LysM PTP1B HFD-fed mice (Fig. 4B). The area under the
curve (AUC) also conﬁrmed that LysM PTP1B mice were
more glucose tolerant than control mice (Fig. 4C). LysM
PTP1B mice were also more insulin tolerant, with de-
creased blood glucose levels at 15, 90, and 120 min post-
insulin injection (Fig. 4D) and decreased AUC during ITT
(Fig. 4E).
Further, acute proinﬂammatory LPS challenge led to
hyperinsulinemia in HFD-fed control mice (75% increase
from basal). Strikingly, LysM PTP1B mice were com-
pletely protected against LPS-induced hyperinsulinemia
(no increase from basal) (Fig. 4F) and post-LPS insulin
levels were signiﬁcantly lower in LysM PTP1B compared
with control mice. Post-LPS blood glucose levels were
also lower in LysM PTP1B mice (Fig. 4G). Additional
measures of metabolic parameters and circulating cyto-
kines are shown in Tables 1 and 2, respectively.
HFD-fed LysM PTP1B and control mice were injected
with either saline or insulin (10 mU/g body weight), and
components of the insulin signaling pathway were in-
vestigated in muscle, liver, and WAT. There were no
signiﬁcant differences in insulin-stimulated insulin re-
ceptor phosphorylation between the two genotypes in
muscle (Fig. 4H), liver, or WAT (Supplementary Figs. 4
and 5, respectively).
F4/80 and CD68 immunohistochemical staining of
WAT from HFD-fed LysM PTP1B mice revealed a trend
toward decreased expression of these markers when
compared with controls (Fig. 4I). To conﬁrm this quan-
titatively, we performed quantitative RT-PCR analysis of
WAT, which showed lower transcript levels of F4/80 and
TNF-a and a trend for decreased expression of CD68 (P =
0.09; two-tailed t test) in LysM PTP1B mice (Fig. 4J),
indicative of decreased macrophage inﬁltration into WAT
and associated inﬂammation. HFD-fed LysM PTP1B mice
also had lower levels of hepatic lipid accumulation (Fig. 4K
and L), which was associated with decreased serum ALT
levels in these mice (Fig. 4M), indicative of improved liver
function. Furthermore, LysM PTP1B mice exhibited in-
creased expression of the antiapoptotic gene BCL2 (Fig. 4N).
HFD-Fed LysM PTP1B Mice Have Increased
Circulating IL-10 Levels, an Elevation in Spleen Cells
Expressing Myeloid Markers, and Increased Levels of
Phosphorylated STAT3 in the Spleen
Basal circulating levels of the anti-inﬂammatory cytokine
IL-10 were elevated in HFD-fed LysM PTP1B compared
with control mice (Fig. 5A). Acute LPS challenge led to an
induction of IL-10 in both control and LysM PTP1B mice,
which led to a further 120% elevation in IL-10 levels in
LysM PTP1B (Fig. 5B). Furthermore, we found a negative
correlation between serum IL-10 and ALT levels (Fig. 5C),
as well as serum IL-10 and insulin levels (Fig. 5D) in HFD
mice following LPS injection, suggesting that elevated
circulating IL-10 levels are strongly associated with the
anti-inﬂammatory role of myeloid PTP1B deﬁciency.
Despite the strong anti-inﬂammatory phenotype of
LysM PTP1B mice, these mice (but not control mice)
developed splenomegaly on HFD (Fig. 5E), with a mean
spleen weight of 0.48 6 0.05 g (n = 14) compared with
0.14 6 0.02 g (n = 13; P # 0.0001; two-tailed t test),
which was also signiﬁcant when corrected for body
weight (Fig. 5F). To assess if these mice were anemic,
hematocrit testing was performed on whole blood, and
no differences were found between LysM PTP1B (36.6 6
1.1%; n = 9) and control mice (38.9 6 1.0%; n = 3).
Hematoxylin and eosin staining of spleen sections
F: Increased IL-10 phosphorylated STAT3 relative to total STAT3 in LysM PTP1B BMDMs compared with control cells following 60-min
(P # 0.05; two-tailed t test) and 120-min (P # 0.01; two-tailed t test) stimulation. G and H: Immunoblot displaying levels of PTP1B protein
present in control and LysM PTP1B BMDMs used for IL-10 and IL-6 stimulations (G) and the correlation between PTP1B protein levels and
levels of phosphorylated STAT3 following 120-min IL-10 stimulation (R2 = 20.51; P # 0.01) (H). I: Immunoblot showing effective PTP1B
knockdown in RAW 264.7 cells transfected with PTP1B short hairpin RNA compared with cells transfected with empty vector only. J and
K: Increased levels of LPS-induced phosphorylated STAT1 (Tyr701) (J) and phosphorylated STAT3 (Tyr705) (K) and iNOS protein were
observed for shPTP1B RAW 264.7 cells compared with vector-only cells. L: Levels of phosphorylated STAT3 (Tyr705) were also elevated
in PTP1B short hairpin RNA RAW 264.7 cells treated with IL-10 during a time-course experiment (30, 60, and 120 min) when compared
with levels in vector-only RAW 264.7 cells. Control, white bars; LysM PTP1B, black bars. Data are expressed as mean 6 SEM. pSTAT,
phosphorylated STAT; shPTP1B, PTP1B short hairpin RNA. *P < 0.05, **P < 0.01.
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Figure 4—LysM PTP1B mice fed an HFD are more glucose and insulin tolerant than littermate controls despite no alteration in body
weight, are protected against LPS-induced hyperinsulinemia, have decreased levels of adipose tissue inﬂammation, and have lower levels
of HF-induced liver damage. A: Body weights for LysM PTP1B mice (n = 5) compared with control mice (n = 6) during an adjusted-calorie
diet containing 55% fat (HFD). B: Following long-term HF dietary feeding, LysM PTP1B mice (n = 5) were more glucose tolerant than
controls (n = 6) 60 min post-glucose injection as determined by GTT (P # 0.05; two-tailed t test). C: GTT results expressed as AUC
showed signiﬁcant improvement in glucose tolerance in the absence of PTP1B (P # 0.05; two-tailed t test). D: ITT of HF-fed LysM PTP1B
mice (n = 8) revealed increased insulin tolerance compared with HF-fed control mice (n = 6) at 15, 90, and 120 min post-insulin (1.1 mU
insulin/g body weight) infusion (two-way ANOVA). E: AUC for ITT was lower for LysM PTP1B mice compared with controls (P# 0.01; two-
tailed t test). F and G: Three hours after administration of 0.5 mg/kg LPS, circulating insulin levels measured in HFD-fed control mice (n = 6)
were signiﬁcantly greater than basal levels (P# 0.05; two-tailed t test), but this was not observed for LysM PTP1B littermates (n = 5). LysM
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revealed unremarkable histology (Fig. 5G). Spleen size
was found to strongly correlate with circulating IL-10
levels under basal and LPS-stimulated states (Fig. 5H
and I). Splenic IL-10 mRNA levels correlated with circu-
lating IL-10 levels following LPS-treatment, suggesting
that the elevation in systemic IL-10 seen in HFD-fed
LysM PTP1B is, at least in part, spleen derived (Fig. 5J).
Flow cytometry analysis of splenocytes established
that the percentage of cells expressing the granulocyte/
monocyte marker Gr1 and the monocyte marker Ly6C
were signiﬁcantly increased in LysM PTP1B cells com-
pared with controls, and a trend for increased expression
of Ly6G was noted (P = 0.09) (Fig. 5K). There were no
alterations in the percentage of cells expressing CD3,
CD4, CD8, B220, CD11c, CD11b, F4/80, and MHCII;
however, when normalized against total cell number,
a signiﬁcant increase in absolute cell numbers expressing
all markers was established for LysM PTP1B mice com-
pared with controls (Supplementary Table 1).
Spleen lysates from HFD-fed LysM PTP1B mice
revealed an increase in the phosphorylation of STAT3a
and STAT3b isoforms compared with control lysates (Fig.
5L and M). Using antibodies against total STAT3, a sig-
niﬁcant increase in the alternatively spliced STAT3b
isoform was noted in LysM PTP1B mice (Fig. 5L and M).
Interestingly, the splenic level of the antiapoptotic pro-
tein BCL2, which is regulated at the gene level by STAT3,
was also increased in these mice, which could contribute
toward the splenomegaly phenotype observed (Fig. 5L
and M).
DISCUSSION
Previous reports have implicated macrophage PTP1B in
the negative regulation of TLR-4-mediated inﬂammatory
signaling; however, these studies have been restricted to
in vitro cell line analysis or characterization of responses
in PTP1B global knockout mice (15–17,25). To de-
ﬁnitively address the role of macrophage PTP1B in in-
ﬂammatory signaling, we have generated mice with
myeloid-speciﬁc PTP1B deletion and interrogated their
whole-body physiology and signaling in isolated macro-
phages. These mice exhibited an LPS-tolerant phenotype
in vivo, which was mirrored by the attenuation of
proinﬂammatory cytokine expression in LPS-treated
BMDMs lacking PTP1B in vitro. A likely explanation for
the downregulation of TNF-a observed in vitro was the
concomitant increase in transcription and secretion of
the anti-inﬂammatory cytokine, IL-10. This was further
reinforced by heightened levels of phosphorylated
STAT3, which is known to mediate IL-10–driven re-
pression of inﬂammatory targets (26). A similar increase
in phosphorylated STAT3 was observed when macro-
phages lacking PTP1B were challenged with IL-10 in
vitro. The IL-10R engage Janus kinase (JAK)1 and Tyk2
following receptor activation, leading to the phosphory-
lation and activation of STAT3 (27,28), and since Tyk2 is
a known substrate of PTP1B (29), this is a plausible
reason for the hyperphosphorylation of STAT3 observed
in the absence of PTP1B. Furthermore, activated STAT3
has been shown to control the expression of the IL-10
promoter, leading to a positive feedback mechanism (30).
In summary, the altered cytokine proﬁle displayed by
these cells and their increased sensitivity to IL-10 may be
responsible, at least in part, for the state of LPS tolerance
observed in LysM PTP1B mice 24 h after receiving low-
dose endotoxin in vivo.
Our in vitro analysis also revealed increased STAT1
phosphorylation, leading to increased iNOS and nitrite
production in LPS-treated LysM PTP1B BMDMs, which
is in agreement with previous ﬁndings of LPS-treated
spleen-macrophages from global knockout mice (17).
Although heightened levels of nitric oxide have been
partly implicated as a cause for increased endotoxin
sensitivity in PTP1B2/2 mice, no such phenotype was
observed in LysM PTP1B mice. These ﬁndings do, how-
ever, add to a large body of evidence that links PTP1B to
the regulation of JAK STAT activation (3,29,31–34).
The anti-inﬂammatory phenotype observed in
endotoxin-challenged LysM PTP1B mice was similarly
replicated in our long-term HFD-feeding study, which is
known to chronically increase plasma LPS concentration
and has thus been termed metabolic endotoxemia (23).
Most remarkably, in vivo LysM PTP1B mice exhibited
increased basal and LPS-induced levels of circulating
IL-10 compared with control animals, which we found to
negatively correlate with insulin and ALT levels. The
insulin-sensitizing effect mediated by IL-10 has been
widely documented before. Low circulating levels of IL-10
PTP1B mice had signiﬁcantly lower circulating insulin (P # 0.01; two-tailed t test) (F) and glucose (G) (P # 0.05; two-tailed t test) than
control mice following LPS injection. H: Muscle tissue immunoblot of insulin signaling pathway components after saline or insulin (10 mU/g
body weight) injection of control or LysM PTP1B mice. I: Representative images of control and LysM PTP1B adipose tissue stained with
F4/80 and CD68 and corresponding quantiﬁcation data. J: RT-PCR analysis of HF-fed mice revealed lower mRNA expression of F4/80 and
TNF-a in adipose tissue extracted from LysM PTP1B animals compared with controls (P# 0.05; two-tailed t test) and a trend for decreased
CD68 expression (P = 0.09; two-tailed t test). K: Liver triglycerides were signiﬁcantly lower in LysM PTP1B tissue compared with controls
(P # 0.001; two-tailed t test). L: Hematoxylin and eosin staining of liver sections show a decreased presence of lipid accumulation in
hepatocytes of LysM PTP1B mice (lower panel) compared with control livers (upper panel).M: Levels of serum ALT were found to be lower
in HF-fed LysM PTP1B mice compared with controls (P # 0.05; two-tailed t test). N: Hepatic expression of antiapoptotic mRNA BCL-2 was
signiﬁcantly upregulated in HF-fed, LPS-treated LysM PTP1B mice compared with controls (P# 0.01; two-tailed t test). Control, white bars
or open circles; LysM PTP1B, black bars or closed circles. Data are expressed as mean 6 SEM. Preﬁx “p,” phosphorylated; +ve, positive.
*P < 0.05, **P < 0.01, ***P < 0.001.
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Figure 5—HF-fed LysM PTP1B mice have increased circulating IL-10 likely to originate from enlarged spleens containing elevated
myeloid cell numbers and increased phosphorylated STAT3 in vivo. A and B: Levels of IL-10 were increased in LysM PTP1B mice (n = 4)
following long-term HF feeding compared with controls (n = 9; 0.13 6 0.04 and 0.03 6 0.006 ng/ml, respectively; P # 0.05; two-tailed
t test) (A) and 3 h after receiving an intraperitoneal dose of 0.5 mg/kg LPS (3.18 6 0.33 and 1.45 6 0.17 ng/ml, respectively; P # 0.001;
two-tailed t test) (B). C and D: Serum IL-10 levels were found to negatively correlate with ALT activity (R2 = 20.38; P < 0.05) (C) and
circulating insulin (R2 = 20.43; P < 0.05) (D) levels. E: Photographs showing spleens harvested from HF-fed LysM PTP1B mice compared
with those from control mice on ﬂ/ﬂ and LysM-Cre backgrounds. F: Increased spleen-to-body-weight ratio for HF-fed LysM PTP1B mice
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have been associated with obese and insulin-resistant
states, as have polymorphisms and haplotypes of the
IL-10 promoter, and IL-10 has been shown to mediate
insulin-sensitizing effects in adipose, liver, and skeletal
muscle by suppressing the deleterious effects of TNF-a
and IL-6 on insulin signaling (35–40). Furthermore,
a shift toward an alternatively activated, anti-inﬂammatory
M2 macrophage phenotype in adipose tissue has been as-
sociated with increased expression of IL-10 (38).
The source of elevated IL-10 in HFD-fed LysM PTP1B
mice suggests it to be splenic in origin, due to the close
correlations noted between circulating IL-10, spleen size,
and splenic IL-10mRNA expression. Further analysis of the
spleens from these mice revealed an increased expression
of the antiapoptotic protein BCL2, which is regulated by
STAT3 and may partly explain the splenomegaly phenotype
(41) and an elevation in the alternatively spliced STAT3b
isoform. Isoform-speciﬁc knockout models have demon-
strated that STAT3b plays a crucial role in inhibiting the
acute inﬂammatory responses, whereby mice lacking
STAT3b showed increased susceptibility and impaired re-
covery following in vivo challenge with LPS (42).
Increased phosphorylation of splenic STAT3 found in
HFD-fed LysM PTP1B mice is in agreement with our in
vitro BMDM studies, as well as a recent study conﬁrming
STAT3 as a substrate of myeloid PTP1B (34), which
demonstrated that global PTP1B2/2 mice are protected
against experimental colitis because of a STAT3/JAK2-
mediated expansion of myeloid-derived suppressor cells
(MDSCs) (34). Our data also provide evidence that this
mechanism is, at least in part, applicable to the anti-
inﬂammatory phenotype observed in HFD-fed LysM
PTP1B mice. States of chronic inﬂammation, which could
be extended to encompass metabolic endotoxemia, are
known to expand immunosuppressive MDSC populations
(CD11b+ Gr+ cells) via elevations in factors such as
proinﬂammatory cytokines, prostanoids, and growth
factors that lead to persistent STAT3 activation (43). In
the absence of myeloid PTP1B, we observe increased
phosphorylated STAT3 in the spleen, elevated numbers
compared with controls (P # 0.01; two-tailed t test). G: Hematoxylin and eosin staining of spleen sections from representative control and
LysM PTP1B mice following HF feeding. H and I: Spleen weight was found to correlate with circulating IL-10 levels in pre-LPS (R2 = 0.83;
P # 0.01) (H) and post-LPS (R2 = 0.76; P # 0.001) (I) states. J: Circulating levels of IL-10 were found to also correlate with levels of splenic
IL-10mRNA (R2 = 0.43; P # 0.05). K: Flow cytometry analysis of spleen cells revealed an increase in the percentage of cells expressing the
monocyte/granulocyte marker Gr1 (P # 0.05; two-tailed t test), the monocyte marker Ly-6C (P # 0.05; two-tailed t test), and the gran-
ulocyte marker Ly6G (P = 0.09). L: Immunoblot displaying increased levels of phosphorylated STAT3a relative to STAT3a (P # 0.01;
two-tailed t test), phosphorylated STAT3b relative to STAT3b (P# 0.05; two-tailed t test), STAT3b, and BCL-2 relative to b-actin (P # 0.01;
two-tailed t test) and BCL-2 (P # 0.01; two-tailed t test) in spleens harvested from HF-fed LysM PTP1B (n = 4) compared with control mice
(n = 4) as quantiﬁed by relative densitometry. M: Control, white bars; LysM PTP1B, black bars. Data are expressed as mean 6 SEM. Wt,
weight; pSTAT, phosphorylated STAT. *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 6—Schematic showing postulated mechanism responsible for the amelioration of hepatic and adipose inﬂammation leading to
improved insulin sensitivity in HF-fed LysM PTP1B mice.
468 Myeloid PTP1B and Inﬂammation Diabetes Volume 63, February 2014
 at University of Aberdeen on January 29, 2014http://diabetes.diabetesjournals.org/Downloaded from 
of splenic cells expressing myeloid markers, and marked
splenomegaly, which would be indicative of MDSC ex-
pansion (43). In addition to the ability of MDSCs to inhibit
T-cell activation (44,45) and NK-cell tumor cytotoxicity
(46), these cells are known to interact with macrophages
by secreting elevated levels of IL-10, which promote mac-
rophage polarization toward the M2 macrophage pheno-
type (47). It is therefore plausible to postulate that in the
absence of myeloid PTP1B, chronic HFD feeding leads to
a STAT3-dependent expansion of IL-10–secreting splenic
MDSCs and possibly M2 macrophages, which alleviate
hepatic and adipose inﬂammation and enhance insulin
sensitivity. Figure 6 displays a schematic depicting the
postulated mechanism responsible for the beneﬁcial
effects observed for HFD-fed LysM PTP1B mice.
In summary, this study provides evidence that LysM
PTP1B mice exhibit improved glucose tolerance and
suppressed inﬂammatory responses in HFD-fed and
endotoxemic mouse models. This is contrary to previous
reports that have assigned an anti-inﬂammatory func-
tion to macrophage PTP1B and will therefore help allay
concerns relating to the application of PTP1B inhibitors
in the clinical setting and open up new avenues for the
use of PTP1B inhibitors as anti-inﬂammatory agents.
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Supplementary Table 1. Gene expression analysis of unstimulated and LPS-stimulated (100ng/ml for 
4hr) control and LysM PTP1B BMDMs. 
 
Gene Treatment Control LysM PTP1B P value 
Mean ± sem Mean ± sem 
IL-12 Unstimulated 1 ± 0.39 1.13 ± 0.07 0.75 
4hr LPS 750931 ± 344883 484493 ± 215365 0.54 
IL-6 Unstimulated 1 ± 0.47 0.02 ± 0.002 0.08 
4hr LPS 25927 ± 8029 29967 ± 10838 0.77 
IL-1β Unstimulated 1 ± 0.27 30.17 ± 29.31 0.35 
4hr LPS 3565223 ± 11968998 4182115 ± 1849572 0.83 
MCP1 Unstimulated 1 ± 0.91 0.76 ± 0.44 0.82 
4hr LPS 49.42 ± 24.68 86.39 ± 41.77 0.48 
Arginase Unstimulated 1 ± 0.18 0.91 ± 0.06 0.66 
4hr LPS 0.6 ± 0.31 0.79 ± 0.26 0.65 
CCL17 Unstimulated 1 ± 1 4.61 ± 1.58 0.1 
4hr LPS 1507.48 ±702.23 2545.28 ±578.68 0.3 
CCL22 Unstimulated 1 ± 0.16 0.97 ± 0.15 0.9 
4hr LPS 1147.15 ± 489.19 2153.93 ± 792.78 0.32 
SOCS3 Unstimulated 1 ± 0.18 0.91 ± 0.06 0.66 
4hr LPS 79.36 ± 26.67 190.24 ± 94.37 0.3 
IL-4RA Unstimulated 1 ± 0.16 1.24 ± 0.24 0.44 
4hr LPS 1.04 ± 0.27 1.74 ± 0.60 0.33 
BCL3 Unstimulated 1 ± 0.54 1 ± 0.39 1 
4hr LPS 7.62 ± 1.46 9.69 ± 2.84 0.54 
BCL2 Unstimulated 1 ± 0.73 0.71 ± 0.29 0.72 
4hr LPS 14.22 ± 4.58 43.55 ± 25.67 0.3 
IKAROS Unstimulated 1 ± 0.76 0.67 ± 0.29 0.70 
4hr LPS 16.42 ± 5.57 55.48 ± 34.50 0.31 
LysM PTP1B mice (n = 4) versus control mice (n = 4). mRNA expression levels calculated relative to reference 
genes (β-actin, YWhaz and NoNo). Data expressed as mean ± S.E.M. Significance value taken as P ≤ 0.05 from 
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Supplementary Table 2. Flow cytometry data showing percentage spleen cells expressing specific cell 
markers and corrected for absolute cell numbers.   
 










CD3+ 28.3 ± 2.2 24.6 ± 1.2 P = 0.3 2.2 ± 0.3 4.2 ± 0.4 ** 
B220+ 54.3 ± 4.2 54.5 ± 3.9 P = 1 4.5 ± 0.3 9.3 ± 0.7 ****  
CD11b+ 6.4 ± 1.0 7.8 ± 2.3 P = 0.5 0.5 ± 0.1 1.4 ± 0.4 *  
CD11c+ 5.18 ± 0.75 5.60 ± 0.43 P = 0.7 0.5 ± 0.1 1.0 ± 0.2 ** 
F4/80+ 12.5 ± 1.2 16.9 ± 1.6 P = 0.06 1.1 ± 0.2 2.9 ± 0.4 *** 
MHCII+ 65.0 ± 4.6 66.4 ± 4.3 P = 0.9 5.5 ± 0.54 11.3 ± 0.70 ****  
Gr1+ See fig 5M   0.4 ± 0.1 1.3 ± 0.7 ** 
Flow cytometry was carried out on spleen cells isolated from HFD-fed LysM PTP1B mice (n = 4) and 
control mice (n = 8). Values on the left side depict the percentage of cells expressing each marker and 
right side shows total number of cells expressing each marker.  Data expressed as mean ± S.E.M. 
Significance value taken as P ≤ 0.05 (*), P≤0.01 (**), P≤0.001 (***), P≤0.0001 (****) from two-tailed 
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Primer sequences  
Arginase F  CAGAAGAATGGAAGAGTCAG 
Arginase R  CAGATATGCAGGGAGTCACC 
 
BCL2 F   GGATGACTTCTCTCGTCGTCGCTAC 
BCL2 R  TGACATCTCCCTGTTGACGCT 
 
BCL3 F   CCGGAGGCCCTTTACTACCA 
BCL3R   GGAGTAGGGGTGAGTAGGCAG 
 
β-actin F  GGGGTGTTGAAGGTCTCAAA 
β-actin R  GATCTGGCACCACACACACCTTTCT 
 
CCL17 F  AGTGCTGCCTGGATTACTTCAAAG 
CCL17 R  CTGGACAGTCAGAAACACGATGG 
 
CCL22 F  TAACATCATGGCTACCCTGCG 
CCL22 R  TGTCTTCCACATTGGCACCA 
 
CD68 F   TGTCTGATCTTGCTAGGACCG 
CD68 R  GAGAGTAACGGCCTTTTTGTGA 
 
F4/80 F   CCCAGCTTATGCCACCTGCA 
F4/80 R   TCCAGGCCCCTGGAACATTGG 
 
FAS F   GGAGGTGGTGATAGCCGGTAT  
FAS R   TGGGTAATCCATAGAGCCCAG 
 
G6Pase F  ATGAACATTCTCCATGACTTTGGG 
G6Pase R  GACAGGGAACTGCTTTATTATAGG 
 
IKAROS F  AGACAAGTGCCTGTCAGACAT 
IKAROS R  CCAGGTAGTTGATGGCATTGTTG 
 
IL1 beta F  GCAACTGTTCCTGAACTCAACT 
IL1 beta R  ATCTTTTGGGGTCCGTCAACT 
 
IL4RA F  TCTGCATCCCGTTGTTTTGC 
IL4RA R  GCACCTGTGCATCCTGAATG 
 
IL6 F   TAGTCCTTCCTACCCCAATTTCC 
IL6 R   TTGGTCCTTAGCCACTCCTTC 
 
IL10 F   GCTCTTACTGACTGGCATGAG 
IL10 R   CGCAGCTCTAGGAGCATGTG 
 
IL12 F   GGAAGCACGGCAGCAGAATA 
IL12 R   AACTTGAGGGAGAAGTAGGAATGG 
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iNOS F   GGAGTGACGGCAAACATGACT 
iNOS R   TAGCCAGCGTACCGGATGA 
 
MCP-1 F  TTAAAAACCTGGATCGGAACCAA 
MCP-1 R  GCATTAGCTTCAGATTTACGGGT 
 
 
TNF-alpha F  CCCTCACACTCAGATCATCTTCT 
TNF-alpha R  GCTACGACGTGGGCTACAG 
 
NoNo F   GCCAGAATGAAGGCTTGACTAT 
NoNo R  TATCAGGGGGAAGATTGCCCA 
 
PEPCK F  GAGATAGCGGCACAAT 
PEPCK R  TTCAGAGACTATGCGGTG 
 
SOCS3 F  ACCAGCGCCACTTCTTCACA 
SOCS3 R  GTGGAGCATCATACTGGTCC 
 
STAT3 F  CAATACCATTGACCTGCCGAT 
STAT3 R  GAGCGACTCAAACTGCCCT 
 
YWhaz F  GAAAAGTTCTTGATCCCCAATGC 
YWhaz R  TGTGACTGGTCCACAATTCCTT 
 
 
Supplementary Figure 1. Immunoblot depicting level of IκBα and phosphorylated c-Jun 
following LPS stimulation (100 ng/ml LPS for 30, 60, 120 min and 24 hr) of LysM-PTP1B (n = 
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Supplementary Figure 2. Immunoblot depicting levels of phosphorylated ERK 1/2 following 




Supplementary Figure 3. Immunoblot depicting levels of phosphorylated IKKα/β, JNK 1/2, 
and p38 following LPS stimulation (100 ng/ml LPS for 30 min) of LysM-PTP1B (n = 4) and 
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Supplementary Figure 4. Liver insulin signaling immunoblot for saline (control, n = 2; LysM-
PTP1B, n = 3) and insulin (control, n = 4; LysM-PTP1B, n = 5) injected mice. 
 
Supplementary Figure 5. WAT insulin signaling immunoblot for saline (control, n = 2; LysM-
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Supplementary Figure 6. Immunohisotchemical staining of adipose tissue from HF-fed control 
(n=4) and LysM-PTP1B (n=4) with iNOS antibody. 
 
  
